內分泌系統癌症中以甲狀腺癌占率最高,而其中有八成為甲狀腺乳突癌。而甲狀腺癌症中以BRAF V600E基因核酸位點突變最常發生。本篇研究主要目的為設立CAST-PCR基因檢測方法針對BRAF V600E進行檢驗。我們共收集200個臨床石蠟包埋組織進行BRAF V600E檢測,檢驗效能分析結果顯示此檢驗方法之臨床檢驗敏感度為81.9%,臨床檢驗特異性為100%,陽性預測值為100%,陰性預測值為83.3%。使用乳突癌細胞株及質體分析之檢驗結果確認,此檢驗方法之最低偵測突變敏感度為1%。同步比對細針抽取細胞學檢查(fine-needle aspiration cytology, FNAC)及石蠟包埋檢體確認兩種檢體之檢驗結果一致。經由以上結果得知,我們所設立的CAST-PCR的檢驗效能佳,利用FNAC檢體即可執行檢驗,得以輔助臨床醫師能精準診斷甲狀腺乳突癌,使臨床治療方針更即時。
Thyroid cancer is the most common malignancy neoplasm in the endocrine system. Papillary thyroid carcinoma (PTC) account for above 80% of thyroid cancers. BRAF V600E is the most commonly mutated gene in thyroid cancer. BRAF V600E mutations were assessed by competitive allele-specific PCR (CAST-PCR) in 200 patients with confirmed papillary thyroid carcinoma or benign findings. The clinical sensitivity was 81.9% and the clinical specificity was 100 %. Positive predictive value was 100% and the negative predictive value was 80.9%. Detection of BRAF V600E by CAST-PCR method in analytical sensitivity was 1%. The BRAF V600E mutation result of paired fine-needle aspiration cytology (FNAC) and FFPE were highly concordant with each other. In this study, we find an efficacy, reliability, and reproducibility CAST-PCR assay to assist in the diagnosis of papillary thyroid carcinoma.
為了持續優化網站功能與使用者體驗,本網站將Cookies分析技術用於網站營運、分析和個人化服務之目的。
若您繼續瀏覽本網站,即表示您同意本網站使用Cookies。